The effect of empagliflozin on improvement of hematopeosis in diabetic cardiovascular patient

Phase 3

Recruiting

• Conditions: Condition 1: Diabetes Mellitus type 2. Condition 2: Coronary artery disease.; Type 2 diabetes mellitus; Atherosclerotic heart disease of native coronary artery; I125.1

• Registration Number: IRCT20190806044451N1
• Lead Sponsor: Zanjan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 November 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

type2 diabetes
age more than 40
stablished cardiovascular disease with angiography
HbA1c between 7 to 9

Exclusion Criteria

heart failure (EF<40 %)
history of myocardial infarction or un stable angina during 6 month ago
Recent anemia
severe kidney disease(GFR<30)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Duration of illness. Timepoint: six month. Method of measurement: questionnaire.;Drug history. Timepoint: six month. Method of measurement: questionnaire.;Empagliflozine. Timepoint: period six month. Method of measurement: questionnaire.;Erythropoetin level. Timepoint: six month. Method of measurement: ELAISA.;Spot albumin to Cr. Timepoint: six month. Method of measurement: dip stick.;Serum hemoglobin levels before and after treatment. Timepoint: six month. Method of measurement: immunoichemilosent.;Echocardiography. Timepoint: six month. Method of measurement: echocardiography device.